Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
Now that most people in North America and Europe are vaccinated and the COVID-19 pandemic is diminishing, Moderna is looking for its second act.
Moderna is preparing for multiple product launches over the next several years, including RSV and flu vaccines and boosters for COVID-19. It is also aiming mRNA programs at rare diseases.
FDA
The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.
FDA
On Wednesday, the FDA authorized new Omicron-specific booster shots for Pfizer-BioNTech and Moderna’s COVID-19 vaccines despite a lack of human data.
Moderna announced it is filing lawsuits against Pfizer and BioNTech, alleging that the companies’ COVID-19 vaccine infringes patents covering its mRNA technology.
A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.
The U.K’s MHRA has granted conditional authorization to Moderna’s newest vaccine candidate, making it the first Omicron-specific COVID-19 booster vaccine approved by a regulatory agency.
While Moderna’s sole marketable program is its COVID-19 vaccine, CEO Stéphane Bancel said the company is “actively working to prepare...new product launches to help patients and drive growth.”
JOBS
  • 2025 Hotbed Maps - Genetown - Elite - Moderna.png
IN THE PRESS